Government-mandated drug safety program effective in reducing prenatal exposure to weight-loss drug phentermine-topiramate
The study authored by Drs. Almut Winterstein and Amir Sarayani was published in the Annals of Internal Medicine journal.
The study authored by Drs. Almut Winterstein and Amir Sarayani was published in the Annals of Internal Medicine journal.
Fourteen members of the class of 2022 were officially inducted at the ASEMFL Annual Meeting in Orlando on Nov. 5.
Research by Patrick Antonelli, M.D., and Almut Winterstein, Ph.D., shows quinolone ear drops used to treat infection increase the risk of tendon ruptures.
Dr. Winterstein was one of nine ISPE members honored with the award at the 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Copenhagen, Denmark.
The model will help regulators, as well as the pharmaceutical industry, evaluate the best- and worst-case scenarios when hormonal contraceptives are prescribed with new drug candidates.
Almut Winterstein, Ph.D., joined the From Florida podcast with Nicci Brown to discuss medical marijuana research.
The study published in the American Journal of Obstetrics and Gynecology highlights the need for women and their providers to carefully examine medications taken during pregnancy.
The U.S. Food and Drug Administration in 2016 took action to reduce the overuse of fluoroquinolones, a type of antibiotic associated with serious side effects. That step helped cut the use of these antibiotics for uncomplicated urinary tract infections, or UTIs, by more than half, according to a University…
The findings are published in July’s issue of Clinical Pharmacology & Therapeutics, the flagship journal of the American Society of Clinical Pharmacology & Therapeutics.
University of Florida researchers determined an FDA-approved program deters pregnant women from starting a potentially harmful immunosuppressive drug. But for women taking the drug, the program was not effective at reducing conception.